Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PLSH | Common Stock | Award | +497K | 497K | Jun 30, 2021 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | PLSH | Stock Options (Right to Buy) | Award | $0 | +497K | $0.00 | 497K | Jun 30, 2021 | Common Stock | 497K | $0.10 | Direct | F2 |
Id | Content |
---|---|
F1 | The shares of common stock of the Issuer were acquired in exchange for shares of common stock of Panacea Life Sciences, Inc. ("Panacea"), in connection with the Securities Exchange Agreement dated June 30, 2021 by and among the Issuer, Panacea and the shareholders of Panacea. |
F2 | One-half of the stock options vest upon the effective date of a 1:28 reverse stock split of the Issuer's common stock, and the remainder vest on June 30, 2022, subject to continued employment with the Issuer. |